Journal
AGEING RESEARCH REVIEWS
Volume 10, Issue 4, Pages 404-412Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.arr.2011.01.003
Keywords
Alzheimer's disease; Behavior; Cholinesterase inhibitors; Attention; Cholinergic hypothesis; Subtypes
Categories
Funding
- Sonexa Therapeutics Inc.
- Lundbeck Canada Inc.
- National Institute of Health
- Ontario Mental Health Foundation
- Canadian Institute of Health Research
- Alzheimer's Society of Canada
- Heart and Stroke Foundation
- Physicians' Services Incorporated Foundation
- Abbott Laboratories
- Workers Safety and Insurance Board (WSIB)
- Lundbeck Canada
Ask authors/readers for more resources
Behavioral and psychological symptoms of dementia (BPSD) include agitation, aberrant motor behavior, anxiety, elation, irritability, depression, apathy, disinhibition, delusions, hallucinations, and sleep or appetite impairment. These symptoms have adverse consequences for patients and caregivers, such as greater impairment in activities of daily living, worsening quality of life and earlier institutionalization. While the etiology of BPSD has not been clearly delineated, studies assessing the benefits of acetylcholinesterase inhibitors on BPSD suggest that some of the neuropsychiatric symptoms of dementia such as agitation, apathy and psychosis may represent a specific central cholinergic deficiency syndrome. Biochemical and neuroimaging studies of BPSD in Alzheimer's patients support these pharmacological data. This review discusses the literature describing the association between cholinergic deficiency and manifestations of BPSD. (C) 2011 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available